***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: BACKGROUND Since the 1990s , fluorouracil-based adjuvant chemotherapy has significantly reduced the risk of tumour recurrence in patients with stage III colon cancer . We aim ed to assess whether the addition of cetuximab to st and ard adjuvant oxaliplatin , fluorouracil , and leucovorin chemotherapy ( FOLFOX4 ) in patients with stage III colon cancer improved disease-free survival ( DFS ) .  METHODS For this open-label , r and omised phase 3 study done in nine European countries , we enrolled patients through an interactive voice response system to the central r and omisation centre , with a central stratified permuted block r and omisation procedure . We r and omly assigned patients with resected ( R0 ) stage III disease ( 1:1 ) to receive 12 cycles of FOLFOX4 twice a week with or without cetuximab . Patients were stratified by N-status ( N1 vs N2 ) , T-status ( T1 - 3 vs T4 ) , and obstruction or perforation status ( no obstruction and no perforation vs obstruction or perforation or both ) . A protocol amendment ( applied in June , 2008 , after 2096 patients had been r and omly assigned to treatment-restricted enrolment to patients with tumours wild-type at codons 12 and 13 in exon 2 of the KRAS gene ( KRAS exon 2 wild-type ) . The primary endpoint was DFS . Analysis was intention to treat in all patients with KRAS exon 2 wild-type tumours . The study is registered at EudraCT , number 2005 - 003463 - 23 . FINDINGS Between Dec 22 , 2005 , and Nov 5 , 2009 , 2559 patients from 340 sites in Europe were r and omly assigned . Of these patients , 1602 had KRAS exon 2 wild-type tumours ( intention-to-treat population ) , 791 in the FOLFOX4 plus cetuximab group and 811 in the FOLFOX4 group .  Median follow-up was 3·3 years ( IQR 3·2 - 3·4 ) . In the experimental and control groups , DFS was similar in the intention-to-treat population ( hazard ratio [ HR ] 1·05 ; 95 % CI 0·85 - 1·29 ; p=0·66 ) , and in patients with KRAS exon 2/BRAF wild-type ( n=984 , HR 0·99 ; 95 % CI 0·76 - 1·28 ) or KRAS exon 2-mutated tumours ( n=742 , HR 1·06 ; 95 % CI 0·82 - 1·37 ) . We noted heterogeneous responses to the addition of cetuximab in preplanned subgroup analyses . Grade 3 or 4 acne-like rash ( in 209 of 785 patients [ 27 % ] vs four of 805 [ < 1 % ] ) , diarrhoea ( 113 [ 14 % ] vs 70 [ 9 % ] ) , mucositis ( 63 [ 8 % ] vs 10 [ 1 % ] ) , and infusion-related reactions ( 55 [ 7 % ] vs 30 [ 4 % ] ) were more frequent in patients treated with FOLFOX4 plus cetuximab than in those patients who received FOLFOX4 alone . INTERPRETATION The addition of cetuximab to FOLFOX4 did not improve DFS compared with FOLFOX4 alone in patients with KRAS exon 2 wild-type resected stage III colon cancer . This trial can not conclude on the benefit of cetuximab in the studied population , but the heterogeneity of response suggests that further investigation of the role of FOLFOX4 plus cetuximab in specific patient subgroups is warranted . FUNDING Fédération Francophone de Cancérologie Digestive ( FFCD ) , Merck KGaA , and Sanofi-Aventis 
    Output:
    
mCRC Patients with left-sided , wild type Kras have a better prognosis than those with right-sided diseases when treated with cetuximab .